In a turbulent environment, investors are inclined to put in some extra work to stay on top of the latest market happenings. Analysts and investors are typically highly focused on company earnings numbers when they are published. Company earnings are a good way to analyze the profitability of the company. Sell-side analysts are currently looking for Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) to post quarterly EPS of $-0.22. The company’s next earnings report is expected to be released on or around 2017-02-23 for the period ending on 2016-12-31. The company posted EPS of $-0.41 for the same quarter last year. Most recently, the company reported EPS of $-0.23. Prior to the last earnings report, Zacks Research had a consensus estimate looking for EPS of $-0.3. The gap between the estimate and actual number was $0.07 which created a surprise factor of 23.33%. The surprise factor can cause substantial stock fluctuations after the earnings release.
Whether a company misses or beats analyst estimates, the earnings report may guide short-term stock price movemments. Investors may also take note of the directional trend of estimates before a company’s earnings report. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) most recently posted actual quarterly EPS of $-0.23 compared to the Zacks Research consensus estimate of $-0.3. The resulting difference was $0.07 creating a surprise factor of 23.33%. 2 brokerage firms are currently covering Merrimack Pharmaceuticals, Inc.. These analysts polled by Zacks Research currently have a mean target price of $7 on the stock. The highest target is currently $7 and the most conservative target sees the stock hitting $7 within the year. In looking at the standard deviation of all estimates, we arrive at 0.
Zacks Research uses an analyst ratings scale from 1 to 5. On this scale, a 1 would represent a Strong Buy, and a 5 rating would signal a Strong Sell recommendation. Combining all the recommendations on Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), the mean currently stands at 3. Breaking those down we see that the ratings are as follows: 0 Strong Buy, 0 Rated Buy, 3 Rated Hold and 0 Rated Sell.
Want to receive stock recommendations on Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) as well as the latest stock picks before the Street? Sign up below!
Analyst recommendations and estimates are for informational purposes only and should be used along with a number of other factors when considering an investment position. Part of the data in this report is derived from Zacks Research and FactSet. Ratings and estimates change daily and thus the numbers may differ slightly if a new report has been issued within the last 24-hours. The consensus numbers take into account the reports from over 160 brokerage firms. The job of analysts is to issue recommendations for their clients, and not typically for the general public. Analyst forecasts, earnings estimates and price target projections are issued to help their clients make money through stock investments. We in no way are suggesting that readers make any decision based on the information in this report.